Belantamab Mafodotin + Bortezomib + Dexamethasone Versus 2L+ Relapsed/Refractory Multiple Myeloma Regimens: Lenalidomide-Exposed, Lenalidomide-Refractory, High-Risk Cytogenic, and 2L-Only Subpopulations: A Network Meta-Analysis

Introduction: Patients with relapsed/refractory multiple myeloma(RRMM) who are refractory to lenalidomide (len) have limited effective treatments and consequently poor outcomes. The phase III DREAMM-7 study (NCT04246047) evaluated belantamab mafodotin (B), an antibody-drug conjugate targeting B-cell...

Full description

Saved in:
Bibliographic Details
Published in:Blood 2024-11, Vol.144 (Supplement 1), p.7054-7054
Main Authors: Rodríguez-Otero, Paula, Richter, Joshua, Nooka, Ajay K., Schjesvold, Fredrik, Combe, Emily, Cooper, Leanne, Schofield, Ollie, Sly, Indeg, Ballew, Nick, Bitetti, Jacopo, Boytsov, Natalie, McNamara, Simon, Purser, Molly
Format: Article
Language:English
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Introduction: Patients with relapsed/refractory multiple myeloma(RRMM) who are refractory to lenalidomide (len) have limited effective treatments and consequently poor outcomes. The phase III DREAMM-7 study (NCT04246047) evaluated belantamab mafodotin (B), an antibody-drug conjugate targeting B-cell maturation antigen, with bortezomib (V)+dexamethasone (d; BVd) vs daratumumab (D)+Vd (DVd) in patients with RRMM who had ≥1 prior line of therapy (2L+) and included patients who were len-exposed/refractory (Hungria et al. NEJM 2024). In the ITT analysis, BVd improved progression-free survival (PFS) vs DVd (36.6 vs 13.4 months; hazard ratio [HR] 0.41, 95% confidence interval 0.31-0.53, P
ISSN:0006-4971
1528-0020
DOI:10.1182/blood-2024-198712